Search

Your search keyword '"Denkert, Carsten"' showing total 1,815 results
Start Over Author "Denkert, Carsten"
1,815 results on '"Denkert, Carsten"'

1. BAG6 restricts pancreatic cancer progression by suppressing the release of IL33-presenting extracellular vesicles and the activation of mast cells

Author

Alashkar Alhamwe, Bilal, Ponath, Viviane, Alhamdan, Fahd, Dörsam, Bastian, Landwehr, Clara, Linder, Manuel, Pauck, Kim, Miethe, Sarah, Garn, Holger, Finkernagel, Florian, Brichkina, Anna, Lauth, Matthias, Tiwari, Dinesh Kumar, Buchholz, Malte, Bachurski, Daniel, Elmshäuser, Sabrina, Nist, Andrea, Stiewe, Thorsten, Pogge von Strandmann, Lisa, Szymański, Witold, Beutgen, Vanessa, Graumann, Johannes, Teply-Szymanski, Julia, Keber, Corinna, Denkert, Carsten, Jacob, Ralf, Preußer, Christian, and Pogge von Strandmann, Elke

Published
2024
Full Text
View/download PDF

2. Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference—a German expert perspective

Author

Krug, David, Banys-Paluchowski, Maggie, Brucker, Sara Y., Denkert, Carsten, Ditsch, Nina, Fasching, Peter A., Haidinger, Renate, Harbeck, Nadia, Heil, Jörg, Huober, Jens, Jackisch, Christian, Janni, Wolfgang, Kolberg, Hans-Christian, Loibl, Sibylle, Lüftner, Diana, van Mackelenbergh, Marion, Radosa, Julia C., Reimer, Toralf, Welslau, Manfred, Würstlein, Rachel, Untch, Michael, and Budach, Wilfried

Published
2024
Full Text
View/download PDF

3. AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication

Author

Monjé, Nanna, Dragomir, Mihnea P., Sinn, Bruno V., Hoffmann, Inga, Makhmut, Anuar, Simon, Tincy, Kunze, Catarina A., Ihlow, Jana, Schmitt, Wolfgang D., Pohl, Jonathan, Piwonski, Iris, Marchenko, Sofya, Keunecke, Carlotta, Calina, Teodor G., Tiso, Francesca, Kulbe, Hagen, Kreuzinger, Caroline, Cacsire Castillo-Tong, Dan, Sehouli, Jalid, Braicu, Elena I., Denkert, Carsten, Darb-Esfahani, Silvia, Kübler, Kirsten, Capper, David, Coscia, Fabian, Morkel, Markus, Horst, David, Sers, Christine, and Taube, Eliane T.

Published
2024
Full Text
View/download PDF

4. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.

Author

Tolaney, Sara, Garrett-Mayer, Elizabeth, Amiri-Kordestani, Laleh, Basho, Reva, Best, Ana, Boileau, Jean-Francois, Denkert, Carsten, Foster, Jared, Harbeck, Nadia, Jacene, Heather, King, Tari, Mason, Ginny, OSullivan, Ciara, Prowell, Tatiana, Richardson, Andrea, Sepulveda, Karla, Smith, Mary, Tjoe, Judy, Turashvili, Gulisa, Woodward, Wendy, Butler, Lynn, Schwartz, Elena, Korde, Larissa, Litton, Jennifer, Regan, Meredith, Pusztai, Lajos, and Rugo, Hope

Subjects
Humans, Female, Breast Neoplasms, Neoadjuvant Therapy, Research Design, Progression-Free Survival
Abstract

PURPOSE: The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007 and updated in 2021 (STEEP 2.0), provide standardized definitions of adjuvant breast cancer (BC) end points. STEEP 2.0 identified a need to separately address end points for neoadjuvant clinical trials. The multidisciplinary NeoSTEEP working group of experts was convened to critically evaluate and align neoadjuvant BC trial end points. METHODS: The NeoSTEEP working group concentrated on neoadjuvant systemic therapy end points in clinical trials with efficacy outcomes-both pathologic and time-to-event survival end points-particularly for registrational intent. Special considerations for subtypes and therapeutic approaches, imaging, nodal staging at surgery, bilateral and multifocal diseases, correlative tissue collection, and US Food and Drug Administration regulatory considerations were contemplated. RESULTS: The working group recommends a preferred definition of pathologic complete response (pCR) as the absence of residual invasive cancer in the complete resected breast specimen and all sampled regional lymph nodes (ypT0/Tis ypN0 per AJCC staging). Residual cancer burden should be a secondary end point to facilitate future assessment of its utility. Alternative end points are needed for hormone receptor-positive disease. Time-to-event survival end point definitions should pay particular attention to the measurement starting point. Trials should include end points originating at random assignment (event-free survival and overall survival) to capture presurgery progression and deaths as events. Secondary end points adapted from STEEP 2.0, which are defined from starting at curative-intent surgery, may also be appropriate. Specification and standardization of biopsy protocols, imaging, and pathologic nodal evaluation are also crucial. CONCLUSION: End points in addition to pCR should be selected on the basis of clinical and biologic aspects of the tumor and the therapeutic agent investigated. Consistent prespecified definitions and interventions are paramount for clinically meaningful trial results and cross-trial comparison.

Published
2023

5. GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer

Author

Möbus, Volker, Lück, Hans-Joachim, Ladda, Ekkehart, Klare, Peter, Engels, Knut, Schmidt, Marcus, Schneeweiss, Andreas, Grischke, Eva-Maria, Wachsmann, Grischa, Forstbauer, Helmut, Untch, Michael, Marmé, Frederik, Blohmer, Jens-Uwe, Jackisch, Christian, Huober, Jens, Stickeler, Elmar, Reinisch, Mattea, Link, Theresa, Sinn, Bruno, Janni, Wolfgang, Denkert, Carsten, Seiler, Sabine, Solbach, Christine, Schmatloch, Sabine, Rey, Julia, and Loibl, Sibylle

Published
2024
Full Text
View/download PDF

9. Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.

Author

Blenman, Kim RM, Marczyk, Michal, Karn, Thomas, Qing, Tao, Li, Xiaotong, Gunasekharan, Vignesh, Yaghoobi, Vesal, Bai, Yalai, Ibrahim, Eiman Y, Park, Tristen, Silber, Andrea, Wolf, Denise M, Reisenbichler, Emily, Denkert, Carsten, Sinn, Bruno V, Rozenblit, Mariya, Foldi, Julia, Rimm, David L, Loibl, Sibylle, and Pusztai, Lajos

Subjects
Genetics, Clinical Research, Cancer, Breast Cancer, 2.1 Biological and endogenous factors, Aetiology, Albumins, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Breast Neoplasms, Cyclophosphamide, Doxorubicin, Female, Humans, Neoadjuvant Therapy, Paclitaxel, Transforming Growth Factor beta, Triple Negative Breast Neoplasms, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeWe examined gene expression, germline variant, and somatic mutation features associated with pathologic response to neoadjuvant durvalumab plus chemotherapy in basal-like triple-negative breast cancer (bTNBC).Experimental designGermline and somatic whole-exome DNA and RNA sequencing, programmed death ligand 1 (PD-L1) IHC, and stromal tumor-infiltrating lymphocyte scoring were performed on 57 patients. We validated our results using 162 patients from the GeparNuevo randomized trial.ResultsGene set enrichment analysis showed that pathways involved in immunity (adaptive, humoral, innate), JAK-STAT signaling, cancer drivers, cell cycle, apoptosis, and DNA repair were enriched in cases with pathologic complete response (pCR), whereas epithelial-mesenchymal transition, extracellular matrix, and TGFβ pathways were enriched in cases with residual disease (RD). Immune-rich bTNBC with RD was enriched in CCL-3, -4, -5, -8, -23, CXCL-1, -3, -6, -10, and IL1, -23, -27, -34, and had higher expression of macrophage markers compared with immune-rich cancers with pCR that were enriched in IFNγ, IL2, -12, -21, chemokines CXCL-9, -13, CXCR5, and activated T- and B-cell markers (GZMB, CD79A). In the validation cohort, an immune-rich five-gene signature showed higher expression in pCR cases in the durvalumab arm (P = 0.040) but not in the placebo arm (P = 0.923) or in immune-poor cancers. Independent of immune markers, tumor mutation burden was higher, and PI3K, DNA damage repair, MAPK, and WNT/β-catenin signaling pathways were enriched in germline and somatic mutations in cases with pCR.ConclusionsThe TGFβ pathway is associated with immune-poor phenotype and RD in bTNBC. Among immune-rich bTNBC RD, macrophage/neutrophil chemoattractants dominate the cytokine milieu, and IFNγ and activated B cells and T cells dominate immune-rich cancers with pCR.

Published
2022

10. Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy

Author

Krug, David, Vladimirova, Valentina, Untch, Michael, Kühn, Thorsten, Schneeweiss, Andreas, Denkert, Carsten, Ataseven, Beyhan, Solbach, Christine, Gerber, Bernd, Tesch, Hans, Golatta, Michael, Seiler, Sabine, Heil, Jörg, Nekljudova, Valentina, Holtschmidt, Johannes, and Loibl, Sibylle

Published
2024
Full Text
View/download PDF

11. PITX2 as a Sensitive and Specific Marker of Midgut Neuroendocrine Tumors: Results from a Cohort of 1157 Primary Neuroendocrine Neoplasms

Author

Grass, Albert, Kasajima, Atsuko, Foersch, Sebastian, Kriegsmann, Mark, Brobeil, Alexander, Schmitt, Maxime, Wagner, Daniel, Poppinga, Jelte, Wiese, Dominik, Maurer, Elisabeth, Kirschbaum, Andreas, Muley, Thomas, Winter, Hauke, Rinke, Anja, Gress, Thomas M., Kremer, Markus, Evert, Matthias, Märkl, Bruno, Quaas, Alexander, Eckstein, Markus, Tschurtschenthaler, Markus, Klöppel, Günter, Denkert, Carsten, Bartsch, Detlef K., and Jesinghaus, Moritz

Published
2024
Full Text
View/download PDF

13. High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma

Author

Jank, Paul, Leichsenring, Jonas, Kolb, Svenja, Hoffmann, Inga, Bischoff, Philip, Kunze, Catarina Alisa, Dragomir, Mihnea P., Gleitsmann, Moritz, Jesinghaus, Moritz, Schmitt, Wolfgang D., Kulbe, Hagen, Sers, Christine, Stenzinger, Albrecht, Sehouli, Jalid, Braicu, Ioana Elena, Westhoff, Christina, Horst, David, Denkert, Carsten, Gröschel, Stefan, and Taube, Eliane T.

Published
2023
Full Text
View/download PDF

14. The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy

Author

Wimberger, Pauline, Blohmer, Jens-Uwe, Krabisch, Petra, Link, Theresa, Just, Marianne, Sinn, Bruno Valentin, Simon, Eike, Solbach, Christine, Fehm, Tanja, Denkert, Carsten, Kühn, Cristin, Rhiem, Kerstin, Tesch, Hans, Kümmel, Sherko, Petzold, Andrea, Stötzer, Oliver, Meisel, Cornelia, Kuhlmann, Jan Dominik, Nekljudova, Valentina, and Loibl, Sibylle

Published
2023
Full Text
View/download PDF

15. Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy

Author

Huober, Jens, van Mackelenbergh, Marion, Schneeweiss, Andreas, Seither, Fenja, Blohmer, Jens-Uwe, Denkert, Carsten, Tesch, Hans, Hanusch, Claus, Salat, Christoph, Rhiem, Kerstin, Solbach, Christine, Fasching, Peter A., Jackisch, Christian, Reinisch, Mattea, Lederer, Bianca, Mehta, Keyur, Link, Theresa, Nekljudova, Valentina, Loibl, Sibylle, and Untch, Michael

Published
2023
Full Text
View/download PDF

18. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Author

El Bairi, Khalid, Haynes, Harry R, Blackley, Elizabeth, Fineberg, Susan, Shear, Jeffrey, Turner, Sophia, de Freitas, Juliana Ribeiro, Sur, Daniel, Amendola, Luis Claudio, Gharib, Masoumeh, Kallala, Amine, Arun, Indu, Azmoudeh-Ardalan, Farid, Fujimoto, Luciana, Sua, Luz F, Liu, Shi-Wei, Lien, Huang-Chun, Kirtani, Pawan, Balancin, Marcelo, El Attar, Hicham, Guleria, Prerna, Yang, Wenxian, Shash, Emad, Chen, I-Chun, Bautista, Veronica, Do Prado Moura, Jose Fernando, Rapoport, Bernardo L, Castaneda, Carlos, Spengler, Eunice, Acosta-Haab, Gabriela, Frahm, Isabel, Sanchez, Joselyn, Castillo, Miluska, Bouchmaa, Najat, Md Zin, Reena R, Shui, Ruohong, Onyuma, Timothy, Yang, Wentao, Husain, Zaheed, Willard-Gallo, Karen, Coosemans, An, Perez, Edith A, Provenzano, Elena, Ericsson, Paula Gonzalez, Richardet, Eduardo, Mehrotra, Ravi, Sarancone, Sandra, Ehinger, Anna, Rimm, David L, Bartlett, John MS, Viale, Giuseppe, Denkert, Carsten, Hida, Akira I, Sotiriou, Christos, Loibl, Sibylle, Hewitt, Stephen M, Badve, Sunil, Symmans, William Fraser, Kim, Rim S, Pruneri, Giancarlo, Goel, Shom, Francis, Prudence A, Inurrigarro, Gloria, Yamaguchi, Rin, Garcia-Rivello, Hernan, Horlings, Hugo, Afqir, Said, Salgado, Roberto, Adams, Sylvia, Kok, Marleen, Dieci, Maria Vittoria, Michiels, Stefan, Demaria, Sandra, and Loi, Sherene

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Breast Cancer, Cancer, Clinical Research, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, International Immuno-Oncology Biomarker Working Group, Clinical sciences, Oncology and carcinogenesis, Epidemiology
Abstract

The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.

Published
2021

19. Automated Scoring of Nuclear Pleomorphism Spectrum with Pathologist-level Performance in Breast Cancer

Author

Mercan, Caner, Balkenhol, Maschenka, Salgado, Roberto, Sherman, Mark, Vielh, Philippe, Vreuls, Willem, Polonia, Antonio, Horlings, Hugo M., Weichert, Wilko, Carter, Jodi M., Bult, Peter, Christgen, Matthias, Denkert, Carsten, van de Vijver, Koen, van der Laak, Jeroen, and Ciompi, Francesco

Subjects
Electrical Engineering and Systems Science - Image and Video Processing, Computer Science - Computer Vision and Pattern Recognition
Abstract

Nuclear pleomorphism, defined herein as the extent of abnormalities in the overall appearance of tumor nuclei, is one of the components of the three-tiered breast cancer grading. Given that nuclear pleomorphism reflects a continuous spectrum of variation, we trained a deep neural network on a large variety of tumor regions from the collective knowledge of several pathologists, without constraining the network to the traditional three-category classification. We also motivate an additional approach in which we discuss the additional benefit of normal epithelium as baseline, following the routine clinical practice where pathologists are trained to score nuclear pleomorphism in tumor, having the normal breast epithelium for comparison. In multiple experiments, our fully-automated approach could achieve top pathologist-level performance in select regions of interest as well as at whole slide images, compared to ten and four pathologists, respectively., Comment: 16 pages, 11 figures

Published
2020

21. Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)

Author

Decker, Thomas, Lüdtke-Heckenkamp, Kerstin, Melnichuk, Luidmila, Hirmas, Nader, Lübbe, Kristina, Zahn, Mark-Oliver, Schmidt, Marcus, Denkert, Carsten, Lorenz, Ralf, Müller, Volkmar, Zahm, Dirk-Michael, Mundhenke, Christoph, Bauer, Stefan, Thill, Marc, Seropian, Peter, Filmann, Natalie, and Loibl, Sibylle

Published
2023
Full Text
View/download PDF

22. Deep learning to predict breast cancer sentinel lymph node status on INSEMA histological images

Author

Marmé, Frederik, Krieghoff-Henning, Eva, Gerber, Bernd, Schmitt, Max, Zahm, Dirk-Michael, Bauerschlag, Dirk, Forstbauer, Helmut, Hildebrandt, Guido, Ataseven, Beyhan, Brodkorb, Tobias, Denkert, Carsten, Stachs, Angrit, Krug, David, Heil, Jörg, Golatta, Michael, Kühn, Thorsten, Nekljudova, Valentina, Gaiser, Timo, Schönmehl, Rebecca, Brochhausen, Christoph, Loibl, Sibylle, Reimer, Toralf, and Brinker, Titus J.

Published
2023
Full Text
View/download PDF

23. LRP1B—a prognostic marker in tubo-ovarian high-grade serous carcinoma

Author

Kolb, Svenja, Hoffmann, Inga, Monjé, Nanna, Dragomir, Mihnea P., Jank, Paul, Bischoff, Philip, Keunecke, Carlotta, Pohl, Jonathan, Kunze, Catarina Alisa, Marchenko, Sofya, Schmitt, Wolfgang D., Kulbe, Hagen, Sers, Christine, Sehouli, Jalid, Braicu, Elena Ioana, Denkert, Carsten, Darb-Esfahani, Silvia, Horst, David, Sinn, Bruno V., and Taube, Eliane T.

Published
2023
Full Text
View/download PDF

24. Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer

Author

Hoffmann, Inga, Dragomir, Mihnea P., Monjé, Nanna, Keunecke, Carlotta, Kunze, Catarina Alisa, Schallenberg, Simon, Marchenko, Sofya, Schmitt, Wolfgang D., Kulbe, Hagen, Sehouli, Jalid, Braicu, Ioana Elena, Jank, Paul, Denkert, Carsten, Darb-Esfahani, Silvia, Horst, David, Sinn, Bruno V., Sers, Christine, Bischoff, Philip, and Taube, Eliane T.

Published
2023
Full Text
View/download PDF

25. The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus

Author

Kaidar-Person, Orit, Pfob, André, Gentilini, Oreste Davide, Borisch, Bettina, Bosch, Ana, Cardoso, Maria João, Curigliano, Giuseppe, De Boniface, Jana, Denkert, Carsten, Hauser, Nik, Heil, Jörg, Knauer, Michael, Kühn, Thorsten, Lee, Han-Byoel, Loibl, Sibylle, Mannhart, Meinrad, Meattini, Icro, Montagna, Giacomo, Pinker, Katja, Poulakaki, Fiorita, Rubio, Isabel T., Sager, Patrizia, Steyerova, Petra, Tausch, Christoph, Tramm, Trine, Vrancken Peeters, Marie-Jeanne, Wyld, Lynda, Yu, Jong Han, Weber, Walter Paul, Poortmans, Philip, and Dubsky, Peter

Published
2023
Full Text
View/download PDF

27. pT3 colorectal cancer revisited: a multicentric study on the histological depth of invasion in more than 1000 pT3 carcinomas—proposal for a new pT3a/pT3b subclassification

Author

Foersch, Sebastian, Lang-Schwarz, Corinna, Eckstein, Markus, Geppert, Carol, Schmitt, Maxime, Konukiewitz, Björn, Groll, Tanja, Schicktanz, Felix, Engel, Jutta, Gleitsmann, Moritz, Westhoff, Christina C., Frickel, Nadine, Litmeyer, Anne-Sophie, Grass, Albert, Jank, Paul, Lange, Sebastian, Tschurtschenthaler, Markus, Wilhelm, Dirk, Roth, Wilfried, Vieth, Michael, Denkert, Carsten, Nagtegaal, Iris, Weichert, Wilko, and Jesinghaus, Moritz

Published
2022
Full Text
View/download PDF

31. An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials

Author

Jank, Paul, primary, Karn, Thomas, additional, van Mackelenbergh, Marion, additional, Lindner, Judith, additional, Treue, Denise, additional, Huober, Jens, additional, Engels, Knut, additional, Solbach, Christine, additional, Diebold, Kurt, additional, Marme, Frederik, additional, Müller, Volkmar, additional, Schneeweiss, Andreas, additional, Sinn, Hans-Peter, additional, Fehm, Tanja, additional, Schem, Christian, additional, Stickeler, Elmar, additional, Fasching, Peter A., additional, Budczies, Jan, additional, Felder, Bärbel, additional, Nekljudova, Valentina, additional, Holtschmidt, Johannes, additional, Untch, Michael, additional, Denkert, Carsten, additional, and Loibl, Sibylle, additional

Published
2024
Full Text
View/download PDF

32. DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer

Author

Brichkina, Anna, primary, Ems, Miriam, additional, Suezov, Roman, additional, Singh, Rajeev, additional, Lutz, Veronika, additional, Picard, Felix S R, additional, Nist, Andrea, additional, Stiewe, Thorsten, additional, Graumann, Johannes, additional, Daude, Michael, additional, Diederich, Wibke E, additional, Finkernagel, Florian, additional, Chung, Ho-Ryun, additional, Bartsch, Detlef K, additional, Roth, Katrin, additional, Keber, Corinna, additional, Denkert, Carsten, additional, Huber, Magdalena, additional, Gress, Thomas M, additional, and Lauth, Matthias, additional

Published
2024
Full Text
View/download PDF

33. Relationship of adaptive subtyping and tumour heterogeneity of treatment response to neoadjuvant therapy in hormone receptor–positive HER2-negative early breast cancer: PENELOPE-B.

Author

Denkert, Carsten, primary, Rachakonda, Krishna, additional, Filipits, Martin, additional, Weber, Karsten, additional, Marmé, Frederik, additional, Untch, Michael, additional, Witkiewicz, Agnieszka K, additional, Im, Seock-Ah, additional, DeMichele, Angela, additional, Pehl, Anika, additional, van 't Veer, Laura, additional, Jank, Paul, additional, Schem, Christian, additional, Fasching, Peter A., additional, Reimer, Toralf, additional, Knudsen, Erik S., additional, Liu, Yuan, additional, Rojo Todo, Federico Gustavo, additional, Turner, Nicholas C., additional, and Loibl, Sibylle, additional

Published
2024
Full Text
View/download PDF

34. Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13).

Author

Metzger, Otto, primary, Ballman, Karla V., additional, Gnant, Michael, additional, Watson, Mark, additional, Chen, Eveline, additional, Tran, Kevin, additional, O'Brien, Patrick, additional, Hlauschek, Dominik, additional, Martin, Miguel, additional, Balko, Justin M, additional, Nowecki, Zbigniew, additional, Hahn, Olwen Mary, additional, Denkert, Carsten, additional, Curtis, Christina, additional, Liu, Yuan, additional, Dueck, Amylou C., additional, Fesl, Christian, additional, Mayer, Erica L., additional, DeMichele, Angela, additional, and Symmans, W. Fraser Fraser, additional

Published
2024
Full Text
View/download PDF

35. Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple‐negative breast cancer patients

Author

Massa, Chiara, primary, Karn, Thomas, additional, Weber, Karsten, additional, Schneeweiss, Andreas, additional, Hanusch, Claus, additional, Uwe Blohmer, Jens, additional, Zahm, Dirk‐Michael, additional, Jackisch, Christian, additional, Mackelenbergh, Marion van, additional, Thomalla, Jörg, additional, Marmé, Frederik, additional, Huober, Jens, additional, Müller, Volkmar, additional, Schem, Christian, additional, Müller, Anja, additional, Stickeler, Elmar, additional, Biehl, Katharina, additional, Fasching, Peter A., additional, Untch, Michael, additional, Loibl, Sibylle, additional, Denkert, Carsten, additional, and Seliger, Barbara, additional

Published
2024
Full Text
View/download PDF

37. Towards computational fluorescence microscopy: Machine learning-based integrated prediction of morphological and molecular tumor profiles

Author

Binder, Alexander, Bockmayr, Michael, Hägele, Miriam, Wienert, Stephan, Heim, Daniel, Hellweg, Katharina, Stenzinger, Albrecht, Parlow, Laura, Budczies, Jan, Goeppert, Benjamin, Treue, Denise, Kotani, Manato, Ishii, Masaru, Dietel, Manfred, Hocke, Andreas, Denkert, Carsten, Müller, Klaus-Robert, and Klauschen, Frederick

Subjects
Computer Science - Computer Vision and Pattern Recognition
Abstract

Recent advances in cancer research largely rely on new developments in microscopic or molecular profiling techniques offering high level of detail with respect to either spatial or molecular features, but usually not both. Here, we present a novel machine learning-based computational approach that allows for the identification of morphological tissue features and the prediction of molecular properties from breast cancer imaging data. This integration of microanatomic information of tumors with complex molecular profiling data, including protein or gene expression, copy number variation, gene methylation and somatic mutations, provides a novel means to computationally score molecular markers with respect to their relevance to cancer and their spatial associations within the tumor microenvironment.

Published
2018

38. Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study

Author

Acs, Balazs, Leung, Samuel C.Y., Kidwell, Kelley M., Arun, Indu, Augulis, Renaldas, Badve, Sunil S., Bai, Yalai, Bane, Anita L., Bartlett, John M.S., Bayani, Jane, Bigras, Gilbert, Blank, Annika, Buikema, Henk, Chang, Martin C., Dietz, Robin L., Dodson, Andrew, Fineberg, Susan, Focke, Cornelia M., Gao, Dongxia, Gown, Allen M., Gutierrez, Carolina, Hartman, Johan, Kos, Zuzana, Lænkholm, Anne-Vibeke, Laurinavicius, Arvydas, Levenson, Richard M., Mahboubi-Ardakani, Rustin, Mastropasqua, Mauro G., Nofech-Mozes, Sharon, Osborne, C. Kent, Penault-Llorca, Frédérique M., Piper, Tammy, Quintayo, Mary Anne, Rau, Tilman T., Reinhard, Stefan, Robertson, Stephanie, Salgado, Roberto, Sugie, Tomoharu, van der Vegt, Bert, Viale, Giuseppe, Zabaglo, Lila A., Hayes, Daniel F., Dowsett, Mitch, Nielsen, Torsten O., Rimm, David L., McShane, Lisa M., Nielsen, Torsten, Leung, Samuel, Borgquist, Signe, Chan, Angela, Denkert, Carsten, Ehinger, Anna, Ellis, Matthew, Flowers, Margaret, Galderisi, Chad, Gholap, Abhi, Hartman, Douglas J., Hugh, Judith C., Jadhav, Anagha, Kornaga, Elizabeth N., Kreipe, Hans, Levenson, Richard, Mastropasqua, Mauro, Moriya, Takuya, Pan, Hongchao, Pantanowitz, Liron, Neri, Ernesta Paola, Polley, Mei-Yin, Ruan, Jason, Sakatani, Takashi, Shepherd, Lois, Smith, Ian, Sparano, Joseph, Spears, Melanie, Srinivasan, Malini, Starczynski, Jane, Todd, Austin, Virk, Shakeel, Wang, Yihong, Yang, Hua, Zhang, Zhiwei, and Zlobec, Inti

Published
2022
Full Text
View/download PDF

39. Prioritization of metabolic genes as novel therapeutic targets in estrogen-receptor negative breast tumors using multi-omics data and text mining

Author

Barupal, Dinesh Kumar, Gao, Bei, Budczies, Jan, Phinney, Brett S, Perroud, Bertrand, Denkert, Carsten, and Fiehn, Oliver

Subjects
Genetics, Biotechnology, Breast Cancer, Cancer, ChemRICH, candidate gene prioritization, metabolic networks, multi-omics, set-enrichment, Oncology and Carcinogenesis
Abstract

Estrogen-receptor negative (ERneg) breast cancer is an aggressive breast cancer subtype in the need for new therapeutic options. We have analyzed metabolomics, proteomics and transcriptomics data for a cohort of 276 breast tumors (MetaCancer study) and nine public transcriptomics datasets using univariate statistics, meta-analysis, Reactome pathway analysis, biochemical network mapping and text mining of metabolic genes. In the MetaCancer cohort, a total of 29% metabolites, 21% proteins and 33% transcripts were significantly different (raw p

Published
2019

41. DNA methylation-based classification of sinonasal tumors

Author

Jurmeister, Philipp, Glöß, Stefanie, Roller, Renée, Leitheiser, Maximilian, Schmid, Simone, Mochmann, Liliana H., Payá Capilla, Emma, Fritz, Rebecca, Dittmayer, Carsten, Friedrich, Corinna, Thieme, Anne, Keyl, Philipp, Jarosch, Armin, Schallenberg, Simon, Bläker, Hendrik, Hoffmann, Inga, Vollbrecht, Claudia, Lehmann, Annika, Hummel, Michael, Heim, Daniel, Haji, Mohamed, Harter, Patrick, Englert, Benjamin, Frank, Stephan, Hench, Jürgen, Paulus, Werner, Hasselblatt, Martin, Hartmann, Wolfgang, Dohmen, Hildegard, Keber, Ursula, Jank, Paul, Denkert, Carsten, Stadelmann, Christine, Bremmer, Felix, Richter, Annika, Wefers, Annika, Ribbat-Idel, Julika, Perner, Sven, Idel, Christian, Chiariotti, Lorenzo, Della Monica, Rosa, Marinelli, Alfredo, Schüller, Ulrich, Bockmayr, Michael, Liu, Jacklyn, Lund, Valerie J., Forster, Martin, Lechner, Matt, Lorenzo-Guerra, Sara L., Hermsen, Mario, Johann, Pascal D., Agaimy, Abbas, Seegerer, Philipp, Koch, Arend, Heppner, Frank, Pfister, Stefan M., Jones, David T. W., Sill, Martin, von Deimling, Andreas, Snuderl, Matija, Müller, Klaus-Robert, Forgó, Erna, Howitt, Brooke E., Mertins, Philipp, Klauschen, Frederick, and Capper, David

Published
2022
Full Text
View/download PDF

43. EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy

Author

Leichsenring, Jonas, Vladimirova, Valentina, Solbach, Christine, Karn, Thomas, Ataseven, Beyhan, Sinn, Bruno Valentin, Barinoff, Jana, Müller, Volkmar, Blohmer, Jens-Uwe, Schem, Christian, Engels, Knut, Marmé, Frederik, Fisseler-Eckhoff, Annette, Fasching, Peter A., Stickeler, Elmar, van Mackelenbergh, Marion, Denkert, Carsten, Stenzinger, Albrecht, Loibl, Sibylle, and Gröschel, Stefan

Published
2022
Full Text
View/download PDF

44. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer

Author

Loi, Sherene, Salgado, Roberto, Adams, Sylvia, Pruneri, Giancarlo, Francis, Prudence A., Lacroix-Triki, Magali, Joensuu, Heikki, Dieci, Maria Vittoria, Badve, Sunil, Demaria, Sandra, Gray, Robert, Munzone, Elisabetta, Drubay, Damien, Lemonnier, Jerome, Sotiriou, Christos, Kellokumpu-Lehtinen, Pirkko Liisa, Vingiani, Andrea, Gray, Kathryn, André, Fabrice, Denkert, Carsten, Piccart, Martine, Roblin, Elvire, and Michiels, Stefan

Published
2022
Full Text
View/download PDF

45. Mesenteric fibrosis in patients with small intestinal neuroendocrine tumors is associated with enrichment of alpha‐smooth muscle actin‐positive fibrosis and COMP‐expressing stromal cells

Author

Graf, Sebastian D., primary, Keber, Corinna U., additional, Hattesohl, Akira, additional, Teply‐Szymanski, Julia, additional, Hattesohl, Sophia, additional, Guder, Marc, additional, Gercke, Norman, additional, Di Fazio, Pietro, additional, Slater, Emily P., additional, Jesinghaus, Moritz, additional, Denkert, Carsten, additional, Bartsch, Detlef K., additional, and Lehman, Bettina, additional

Published
2024
Full Text
View/download PDF

46. Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer

Author

Jahangir, Chowdhury Arif, primary, Page, David B, additional, Broeckx, Glenn, additional, Gonzalez, Claudia A, additional, Burke, Caoimbhe, additional, Murphy, Clodagh, additional, Reis‐Filho, Jorge S, additional, Ly, Amy, additional, Harms, Paul W, additional, Gupta, Rajarsi R, additional, Vieth, Michael, additional, Hida, Akira I, additional, Kahila, Mohamed, additional, Kos, Zuzana, additional, van Diest, Paul J, additional, Verbandt, Sara, additional, Thagaard, Jeppe, additional, Khiroya, Reena, additional, Abduljabbar, Khalid, additional, Acosta Haab, Gabriela, additional, Acs, Balazs, additional, Adams, Sylvia, additional, Almeida, Jonas S, additional, Alvarado‐Cabrero, Isabel, additional, Azmoudeh‐Ardalan, Farid, additional, Badve, Sunil, additional, Baharun, Nurkhairul Bariyah, additional, Bellolio, Enrique R, additional, Bheemaraju, Vydehi, additional, Blenman, Kim RM, additional, Botinelly Mendonça Fujimoto, Luciana, additional, Burgues, Octavio, additional, Chardas, Alexandros, additional, Cheang, Maggie Chon U, additional, Ciompi, Francesco, additional, Cooper, Lee AD, additional, Coosemans, An, additional, Corredor, Germán, additional, Dantas Portela, Flavio Luis, additional, Deman, Frederik, additional, Demaria, Sandra, additional, Dudgeon, Sarah N, additional, Elghazawy, Mahmoud, additional, Fernandez‐Martín, Claudio, additional, Fineberg, Susan, additional, Fox, Stephen B, additional, Giltnane, Jennifer M, additional, Gnjatic, Sacha, additional, Gonzalez‐Ericsson, Paula I, additional, Grigoriadis, Anita, additional, Halama, Niels, additional, Hanna, Matthew G, additional, Harbhajanka, Aparna, additional, Hart, Steven N, additional, Hartman, Johan, additional, Hewitt, Stephen, additional, Horlings, Hugo M, additional, Husain, Zaheed, additional, Irshad, Sheeba, additional, Janssen, Emiel AM, additional, Kataoka, Tatsuki R, additional, Kawaguchi, Kosuke, additional, Khramtsov, Andrey I, additional, Kiraz, Umay, additional, Kirtani, Pawan, additional, Kodach, Liudmila L, additional, Korski, Konstanty, additional, Akturk, Guray, additional, Scott, Ely, additional, Kovács, Anikó, additional, Lænkholm, Anne‐Vibeke, additional, Lang‐Schwarz, Corinna, additional, Larsimont, Denis, additional, Lennerz, Jochen K, additional, Lerousseau, Marvin, additional, Li, Xiaoxian, additional, Madabhushi, Anant, additional, Maley, Sai K, additional, Manur Narasimhamurthy, Vidya, additional, Marks, Douglas K, additional, McDonald, Elizabeth S, additional, Mehrotra, Ravi, additional, Michiels, Stefan, additional, Kharidehal, Durga, additional, Minhas, Fayyaz ul Amir Afsar, additional, Mittal, Shachi, additional, Moore, David A, additional, Mushtaq, Shamim, additional, Nighat, Hussain, additional, Papathomas, Thomas, additional, Penault‐Llorca, Frederique, additional, Perera, Rashindrie D, additional, Pinard, Christopher J, additional, Pinto‐Cardenas, Juan Carlos, additional, Pruneri, Giancarlo, additional, Pusztai, Lajos, additional, Rajpoot, Nasir Mahmood, additional, Rapoport, Bernardo Leon, additional, Rau, Tilman T, additional, Ribeiro, Joana M, additional, Rimm, David, additional, Vincent‐Salomon, Anne, additional, Saltz, Joel, additional, Sayed, Shahin, additional, Hytopoulos, Evangelos, additional, Mahon, Sarah, additional, Siziopikou, Kalliopi P, additional, Sotiriou, Christos, additional, Stenzinger, Albrecht, additional, Sughayer, Maher A, additional, Sur, Daniel, additional, Symmans, Fraser, additional, Tanaka, Sunao, additional, Taxter, Timothy, additional, Tejpar, Sabine, additional, Teuwen, Jonas, additional, Thompson, E Aubrey, additional, Tramm, Trine, additional, Tran, William T, additional, van der Laak, Jeroen, additional, Verghese, Gregory E, additional, Viale, Giuseppe, additional, Wahab, Noorul, additional, Walter, Thomas, additional, Waumans, Yannick, additional, Wen, Hannah Y, additional, Yang, Wentao, additional, Yuan, Yinyin, additional, Bartlett, John, additional, Loibl, Sibylle, additional, Denkert, Carsten, additional, Savas, Peter, additional, Loi, Sherene, additional, Specht Stovgaard, Elisabeth, additional, Salgado, Roberto, additional, Gallagher, William M, additional, and Rahman, Arman, additional

Published
2024
Full Text
View/download PDF

47. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

Author

Aebi, Stephan, André, Fabrice, Barrios, Carlos, Bergh, Jonas, Bonnefoi, Herve, Bretel Morales, Denisse, Brucker, Sara, Burstein, Harold, Cameron, David, Cardoso, Fatima, Carey, Lisa, Chua, Boon, Ciruelos, Eva, Colleoni, Marco, Curigliano, Giuseppe, Delaloge, Suzette, Denkert, Carsten, Dubsky, Peter, Ejlertsen, Bent, Fitzal, Florian, Francis, Prudence, Galimberti, Viviana, Gamal El Din Mohamed Mahmoud, Hebatallah, Garber, Judy, Gnant, Michael, Gradishar, William, Gulluoglu, Bahadir, Harbeck, Nadia, Huang, Chiun-Sheng, Huober, Jens, Ilbawi, Andre, Jiang, Zefei, Johnston, Steven, Lee, Eun Sook, Loibl, Sibylle, Morrow, Monica, Partridge, Ann, Piccart, Martine, Poortmans, Philip, Prat, Aleix, Regan, Meredith, Rubio, Isabella, Rugo, Hope, Rutgers, Emiel, Sedlmayer, Felix, Semiglazov, Vladimir, Senn, Hans-Joerg, Shao, Zhiming, Spanic, Tanja, Tesarova, Petra, Thürlimann, Beat, Tjulandin, Sergei, Toi, Masakazu, Trudeau, Maureen, Turner, Nicholas, Vaz Luis, Inez, Viale, Giuseppe, Watanabe, Toru, Weber, Walter P., Winer, Eric P., Xu, Binghe, Burstein, H.J., Curigliano, G., Thürlimann, B., Weber, W.P., Poortmans, P., Regan, M.M., Senn, H.J., Winer, E.P., and Gnant, M.

Published
2021
Full Text
View/download PDF

48. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

Author

Denkert, Carsten, Seither, Fenja, Schneeweiss, Andreas, Link, Theresa, Blohmer, Jens-Uwe, Just, Marianne, Wimberger, Pauline, Forberger, Almuth, Tesch, Hans, Jackisch, Christian, Schmatloch, Sabine, Reinisch, Mattea, Solomayer, Erich F, Schmitt, Wolfgang D, Hanusch, Claus, Fasching, Peter A, Lübbe, Kristina, Solbach, Christine, Huober, Jens, Rhiem, Kerstin, Marmé, Frederik, Reimer, Toralf, Schmidt, Marcus, Sinn, Bruno V, Janni, Wolfgang, Stickeler, Elmar, Michel, Laura, Stötzer, Oliver, Hahnen, Eric, Furlanetto, Jenny, Seiler, Sabine, Nekljudova, Valentina, Untch, Michael, and Loibl, Sibylle

Published
2021
Full Text
View/download PDF

49. Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment

Author

Terrisse, Safae, Derosa, Lisa, Iebba, Valerio, Ghiringhelli, François, Vaz-Luis, Ines, Kroemer, Guido, Fidelle, Marine, Christodoulidis, Stergios, Segata, Nicola, Thomas, Andrew Maltez, Martin, Anne-Laure, Sirven, Aude, Everhard, Sibille, Aprahamian, Fanny, Nirmalathasan, Nitharsshini, Aarnoutse, Romy, Smidt, Marjolein, Ziemons, Janine, Caldas, Carlos, Loibl, Sibylle, Denkert, Carsten, Durand, Sylvere, Iglesias, Claudia, Pietrantonio, Filippo, Routy, Bertrand, André, Fabrice, Pasolli, Edoardo, Delaloge, Suzette, and Zitvogel, Laurence

Published
2021
Full Text
View/download PDF

50. Frühes Mammakarzinom: Aktuelle Strategien in der System- und Radiotherapie: 17. Internationale St.-Gallen-Konsensuskonferenz vor dem Hintergrund deutscher Therapieempfehlungen diskutiert

Author

Schneeweiss, Andreas, Huober, Jens, Brucker, Sara Y., Budach, Wilfried, Denkert, Carsten, Fasching, Peter A., Haidinger, Renate, Harbeck, Nadia, Jackisch, Christian, Janni, Wolfgang, Krug, David, Kühn, Thorsten, Loibl, Sibylle, Müller, Volkmar, Thill, Marc, Thomssen, Christoph, Untch, Michael, Kolberg-Liedtke, Cornelia, and Lüftner, Diana

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results